Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.

ABSTRACT:

Background

Evidence on the cardiovascular benefits of combining empagliflozin with glucagon-like peptide-1 receptor agonists (GLP-1RA) is limited, derived primarily from indirect comparisons or subgroup analyses of cardiovascular outcome trials.

Methods

We conducted a cohort study emulating two comparative effectiveness trials using US healthcare databases (2013-2022), including federal Medicare and commercial claims data (Optum Clinformatics and MarketScan). Among adults with type 2 diabetes in routine care, we compared cardiovascular outcomes in patients initiating: (i) empagliflozin first, followed by augmentation with either GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i), and (ii) GLP-1RA first, followed by augmentation with either empagliflozin or sulfonylureas.

SUBMITTER: Htoo PT 

PROVIDER: S-EPMC13644152 | biostudies-literature | 2026 Jul

REPOSITORIES: biostudies-literature